Branchenkontext
Madrigal Pharmaceuticals [MDGL]
Zuletzt aktualisiert 24 Jun 2026 @ 16:00 (Exchange is closed)
Letzter Kurs: $509.76
-0.71%
1.22
GaG Algo Score™
v1.0
Kurz
1.22
Mittel
2.35
Lang
3.19
KAUF
80.00%
Rendite 32.19%
VERKAUF
77.55%
Rendite 27.40%
Linie
Pivot-Daten
Pivot-Statistik
| Kennzahl | Durchschnitt | Median | Std.-Abw. |
|---|---|---|---|
| Gewinn % | 13.37% | 13.37% | 0.00% |
| Verlust % | -17.19% | -17.19% | 0.00% |
| Dauer | 41.0d | 41d | 28.3d |
| Gefundene Pivots gesamt | 3 |
| Gewinn-/Verlustphasen | 2 (1 Gewinn / 1 Verlust) |
| Letzter Pivot | Top @ $513.43 am 2026-06-23 |
| Änderung seit letztem Pivot | $0.00 (0.00%) |
Nächste Pivot-Prognose Letzter Kurs: $509.76
| Erwarteter nächster Typ | Bottom |
| Erwarteter Preis (Durchschn.) | $425.15 |
| Erwarteter Preis (Median) | $425.15 |
| Erwarteter Preisbereich (~68%) | $425.15 - $425.15 |
| Änderung zum Durchschnittsziel | $-84.61 (-16.60%) |
| Erwartetes Datum (Durchschn.) | 2026-08-03 |
| Erwarteter Datumsbereich (~68%) | 2026-07-05 - 2026-08-31 |
| Basis | Based on 1 historical losses (Avg: -17.19%, Median: -17.19%, StdDev of Abs: 0.00%) and duration (Avg: 41.0 days, StdDev: 28.3 days) |
| Hinweis | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Slight gain for Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals (MDGL) stock price slightly increased on Tuesday after the stock rose $0.550 (0.11%) from the previous session on normal volume. The stock held up slightly better than the falling NASDAQ (-0.43% down).(The stock has risen 3 days straight. This extended rally increases the chances of a price pullback soon) With 266 382 shares traded, volume yesterday reached $136.77M. This was 15 462 shares less than the prior day. Compared to the 10-day average of 296 898 shares, volume was less than the average.
Madrigal Pharmaceuticals signals
There is no conclusive signals given from RSI. The price is above both moving averages, but the short-term average remains below the long-term average; upward momentum is present but not yet fully confirmed. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (20%), medium- (20%), and long-term (20%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Madrigal Pharmaceuticals Support & Resistance Levels
The stock is approaching the closest resistance level at $514.00. approximately $0.570 (0.11%) away. Pushing up towards resistance. Breaking above this level could signal further upside where next resistance level will be found at $519. On a fall back there will be support at $445 The dis das resistance s1445 -
Madrigal Pharmaceuticals Evaluation
- Kurz Score: 1.22
- Mittel Score: 2.35
- Lang Score: 3.19
Eigentümerfluss
GetAGraph InsiderPower
Transaktionen
691
Kaufkraft
332.98M
Verkaufskraft
367.14M
Zuverlässigkeit
100/100
Kauf / Verkauf
0.91
Hist. Korr.
0.27
Letztes Signal
Sell 2026-06-10
Director 519
Officer 149
Executive 23
2026-06-17
Taub Rebecca Director
Buy 454
2026-06-17
Taub Rebecca Director
Buy 766
2026-06-17
Levy Richard S Director
Buy 454
2026-06-17
Levy Richard S Director
Buy 766
2026-06-17
Fouse Jacqualyn A Director
Buy 454
2026-06-17
Fouse Jacqualyn A Director
Buy 766
Beziehungsprofil
Korrelationsbild
<span style="background-color: lightgreen">Undervalued: <i class="arrow arrow-up"></i>0.63% <strong>$514.15</strong> paired level.</span>
Positioning pressure
Short interest pressure
Short interest
17.24%
Of outstanding shares
Short float
18.53%
Of tradable float
Days to cover
14.08
Short interest divided by average volume
Squeeze probability
81.80%
-1.91% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
10
EPS beats
5
EPS misses
5
Avg. surprise
3.76%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3/2025 | 2025-10-29 | - | - | - | - |
| Q2/2025 | 2025-08-06 | - | $-3.64 | - | - |
| Q1/2025 | 2025-05-01 | $-3.32 | $-3.62 | 8.29% | 137.25M |
| Q4/2024 | 2025-02-26 | $-2.71 | $-4.32 | 37.27% | 103.32M |
| Q3/2024 | 2024-10-31 | $-4.92 | $-6.94 | 29.11% | 62.18M |
| Q2/2024 | 2024-08-07 | $-7.10 | $-7.55 | 5.96% | 14.64M |
| Q1/2024 | 2024-05-07 | $-7.38 | $-6.06 | -21.78% | - |
| Q4/2023 | 2024-02-28 | $-5.68 | $-5.32 | -6.77% | 770 000 |
Analyst view
Analyst targets
Consensus
$656.00
Median
$579.00
Low
$542.00
High
$964.00
News flow
Latest company news
Market coverage
globenewswire.com Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) Jun 22, 2026 fool.com 3 Under-the-Radar Stocks to Buy and Hold for a Decade Jun 16, 2026 seekingalpha.com Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Jun 10, 2026 zacks.com Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound? Jun 5, 2026Company releases
Company context
Company profile
Börse:
NASDAQ
Sektor:
Healthcare
Branche:
Biotechnology
Currency
USD
Madrigal Pharmaceuticals Inc is a biopharmaceutical company in the clinical development phase concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular metabolic and liver disorders Its most advanced drug candidate resmetirom functions as a livertargeted selective thyroid hormone receptorss agonist currently undergoing latestage Phase III clinical trials for managing nonalcoholic steatohepatitis NASH The companys pipeline also features MGL3745 which serves as a secondary or backup compound to resmetirom Madrigal holds a collaborative agreement with HoffmannLa Roche encompassing research development and commercialization activities The companys operations are based out of West Conshohocken Pennsylvania
Navigation